leisure time -WSS

leisure time

author：leisure time 2025-09-30 23:19:19 - browse：138

Astrazeneca office building -- health policy coverage from STAT — AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Study links childhood stress with decline in older age

WSS

Leukemia patients are helped by Syndax's new type of therapy

Americans' trust in science, scientist continues decline: Report

After sickle

Biotech startup Celsius cuts 75% of staff ahead of first trial start

'Null' research findings aren't empty of meaning. Let's publish them

After sickle

focus

leisure time

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Biotech startup Celsius cuts 75% of staff ahead of first trial start

At least 13 dead in Texas as scorching temps continue

CDC recommends RSV monoclonal antibody for infants

23andMe had bad news about my health. I wish a person had delivered it

Study links childhood stress with decline in older age

In age of alternative facts, a scholarly course on calling out crap

Radiology is caught between AI's potential and concern for patients

Affirmative action in medical school literally saved lives

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

hotspot

How to ethically and practically extend health care to all

Patients' immediate access to test results puts radiologists in a bind

The woman behind the Dana Farber

Roche to buy Carmot Therapeutics, developer of obesity drugs

Americans' trust in science, scientist continues decline: Report

Biotech startup Celsius cuts 75% of staff ahead of first trial start

focus

hotspot

hotspot

explore